inPractice® - NNRTIs and Dyslipidemia

Metabolic Complications of HIV and Antiretroviral Therapy: Dyslipidemia, Insulin Resistance, and Cardiovascular Disease

Authors: Judith S. Currier, MD, MSc; Risa Hoffman, MD, MPH (More Info)
Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
Last Reviewed: 10/10/18 (What's New)

Summary

Lipid effects of NNRTIs vary (Table 2)
- Efavirenz is associated with increases in TC and TG, although TC/HDL ratio generally remains unchanged^{[Young 2005]}
  - Efavirenz has been shown to have greater lipid effects than atazanavir/ritonavir^{[Riddler 2008; Daar 2011]}

Action required

Login now to access all of your entitled content
or
View additional options to gain access to this content

Keywords: Dyslipidemia, Treatment Complications